Therapy of hypertension;Hypertonietherapie

Clinical Research in Cardiology

Volumn 95, Issue SUPPL. 6, 2006, Pages

  Kreutz, R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antihypertensives; Guidelines; Therapy of hypertension

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; HUMAN; HYPERTENSION; KIDNEY DISEASE; REVIEW; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; RECURRENCE;

EID: 33749402600     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-006-1807-3     Document Type: Review

References (17)

1. ASCOT-Studie: Dahlof B, Sever PS, Poulter NR et al (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366:895
2. Barnett A et al (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952
3. Brenner BM, Cooper ME, de Zeeuw D et al (2002) for the RENAAL study investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861
4. Chobanian AV, Bakris GL, Black HR et al (2003) and the National High Blood Pressure Education Program Coordinating Committee: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206
5. Dahlöf B, Devereux RB, Kjeldsen SE et al (2002) for the LIFE study group: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995
6. Hansson L, Zanchetti A Carruthers S G et al (1998) Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 351:1755
7. http://www.g-ba.de/cms/upload/pdf/abs5/richtlinien/AMR-An16 2004-06-15.pdf
8. http://www.paritaet.org/RR-Liga/indexv4.htm
9. Julius S, Kjeldsen SE, Weber M, Brunner H R, Ekman S, Hansson L, Hua T, Laragh J, McInnes G T, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, and VALUE trial group (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 :2022
10. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365: 217
11. Lewis EJ, Hunsicker LG, Clarke WR et al for the collaborative study group (2001) Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851
12. National Institute for Clinical Excellence: Clinical Guidelines 18 Hypertension: management of hypertension in adults in primary care. 2004:1 http://www.nice.org.uk/pdf/CG018NICEguideline.pdf
13. Parving HH, Lehnert H, Bröchner-Mortensen J et al (2001) for the irbesartan in patients with type 2 diabetes and microalbuminuria study group: the effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870
14. PROGRESS collaborative group (2001) Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033
15. Schrader J, Lüders S, Kulschewski A et al (2005) Morbidity and mortality after stroke, Eprosartan compared with Nitrendipine for secondary prevention. Stroke, p 1218
16. Weber MA, Julius S, Kjeldsen SE et al (2004) Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 363:2049
17. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011